The Role of Gut Microbiota Modification in Nonalcoholic Fatty Liver Disease Treatment Strategies.

IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY International Journal of Hepatology Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI:10.1155/2024/4183880
Hessam Yaghmaei, Amirhossein Bahanesteh, Masood Soltanipur, Sobhan Takaloo, Mahdi Rezaei, Seyed Davar Siadat
{"title":"The Role of Gut Microbiota Modification in Nonalcoholic Fatty Liver Disease Treatment Strategies.","authors":"Hessam Yaghmaei, Amirhossein Bahanesteh, Masood Soltanipur, Sobhan Takaloo, Mahdi Rezaei, Seyed Davar Siadat","doi":"10.1155/2024/4183880","DOIUrl":null,"url":null,"abstract":"<p><p>One of the most common chronic liver diseases is nonalcoholic fatty liver disease (NAFLD), which affects many people around the world. Gut microbiota (GM) dysbiosis seems to be an influential factor in the pathophysiology of NAFLD because changes in GM lead to fundamental changes in host metabolism. Therefore, the study of the effect of dysbiosis on the pathogenicity of NAFLD is important. European clinical guidelines state that the best advice for people with NAFLD is to lose weight and improve their lifestyle, but only 40% of people can achieve this goal. Accordingly, it is necessary to provide new treatment approaches for prevention and treatment. In addition to dietary interventions and lifestyle modifications, GM modification-based therapies are of interest. These therapies include probiotics, synbiotics, fecal microbiota transplantation (FMT), and next-generation probiotics. All of these treatments have had promising results in animal studies, and it can be imagined that acceptable results will be obtained in human studies as well. However, further investigations are required to generalize the outcomes of animal studies to humans.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11498984/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/4183880","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

One of the most common chronic liver diseases is nonalcoholic fatty liver disease (NAFLD), which affects many people around the world. Gut microbiota (GM) dysbiosis seems to be an influential factor in the pathophysiology of NAFLD because changes in GM lead to fundamental changes in host metabolism. Therefore, the study of the effect of dysbiosis on the pathogenicity of NAFLD is important. European clinical guidelines state that the best advice for people with NAFLD is to lose weight and improve their lifestyle, but only 40% of people can achieve this goal. Accordingly, it is necessary to provide new treatment approaches for prevention and treatment. In addition to dietary interventions and lifestyle modifications, GM modification-based therapies are of interest. These therapies include probiotics, synbiotics, fecal microbiota transplantation (FMT), and next-generation probiotics. All of these treatments have had promising results in animal studies, and it can be imagined that acceptable results will be obtained in human studies as well. However, further investigations are required to generalize the outcomes of animal studies to humans.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肠道微生物群改变在非酒精性脂肪肝治疗策略中的作用。
非酒精性脂肪肝(NAFLD)是最常见的慢性肝病之一,影响着世界各地的许多人。肠道微生物群(GM)失调似乎是非酒精性脂肪肝病理生理学的一个影响因素,因为肠道微生物群的变化会导致宿主新陈代谢发生根本性变化。因此,研究菌群失调对非酒精性脂肪肝致病性的影响非常重要。欧洲临床指南指出,对非酒精性脂肪肝患者的最佳建议是减轻体重和改善生活方式,但只有 40% 的人能实现这一目标。因此,有必要提供新的预防和治疗方法。除了饮食干预和生活方式调整外,基于基因改造的疗法也备受关注。这些疗法包括益生菌、合成益生菌、粪便微生物群移植(FMT)和新一代益生菌。所有这些疗法在动物实验中都取得了可喜的成果,可以想象在人体实验中也会取得可接受的结果。然而,要将动物实验的结果推广到人类身上,还需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International Journal of Hepatology
International Journal of Hepatology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
3.80
自引率
0.00%
发文量
11
审稿时长
15 weeks
期刊介绍: International Journal of Hepatology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to the medical, surgical, pathological, biochemical, and physiological aspects of hepatology, as well as the management of disorders affecting the liver, gallbladder, biliary tree, and pancreas.
期刊最新文献
Utilization of Contrast-Enhanced Ultrasound in Diagnosis of Focal Liver Lesions. Anatomical Variations of the Gallbladder and Bile Ducts: An MRI Study. The Role of Gut Microbiota Modification in Nonalcoholic Fatty Liver Disease Treatment Strategies. Evaluation of Noninvasive Tools for Predicting Esophageal Varices in Patients With Cirrhosis at Tygerberg Hospital, Cape Town. Impact of Renal Replacement Therapy on Outcomes of Living Donor Liver Transplantation for Acute Liver Failure: A Cohort Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1